SEARCH

SEARCH BY CITATION

REFERENCES

  • Arlt VM, Stiborova M, Schmeiser HH. 2002. Aristolochic acid as a probable human cancer hazard in herbal remedies: A review. Mutagenesis 17: 265277.
  • Attaluri S, Bonala RR, Yang IY, Lukin MA, Wen Y, Grollman AP, Moriya M, Iden CR, Johnson F. 2010. DNA adducts of aristolochic acid II: Total synthesis and site-specific mutagenesis studies in mammalian cells. Nucleic Acids Res 38: 339352.
  • Bamias G, Boletis J. 2008. Balkan nephropathy: Evolution of our knowledge. Am J Kidney Dis 52: 606616.
  • Batuman V. 2006. Fifty years of Balkan endemic nephropathy: daunting questions, elusive answers. Kidney Int 69: 644646.
  • Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, Gnatenko DV, Wu L, Turesky RJ, Wu XR, Pu YS, Grollman AP. 2012. Aristolochic acid-associated urothelial cancer in Taiwan. Proc Natl Acad Sci USA 109: 82418246.
  • Clark HA, Snedeker SM. 2006. Ochratoxin A: Its cancer risk and potential for exposure. J Toxicol Environ Health B Crit Rev 9: 265296.
  • Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C. 1994. Chinese herbs nephropathy: A clue to Balkan endemic nephropathy? Kidney Int 45: 16801688.
  • Cosyns JP, Jadoul M, Squifflet JP, Wese FX, van Ypersele de Strihou C. 1999. Urothelial lesions in Chinese-herb nephropathy. Am J Kidney Dis 33: 10111017.
  • Dawson WR. 1927. A study of the progress of medical botany through twenty-two centuries. Pharm J Pharmacist: 396–397;427430.
  • De Broe ME. 2012. Chinese herbs nephropathy and Balkan endemic nephropathy: Toward a single entity, aristolochic acid nephropathy. Kidney Int 81: 513515.
  • de Jonge H, Vanherweghem JL. 2008. Aristolochic acid: The common culprit of Chinese herbs nephropathy and Balkan endemic nephropathy. Nephrol Dial Transplant 23: 3941.
  • Debelle FD, Vanherweghem JL, Nortier JL. 2008. Aristolochic acid nephropathy: A worldwide problem. Kidney Int 74: 158169.
  • Dickman KG, Sweet DH, Bonala R, Ray T, Wu A. 2011. Physiological and molecular characterization of aristolochic acid transport by the kidney. J Pharmacol Exp Ther 338: 588597.
  • Djukanović L, Radovanović Z. 2003. Balkan endemic nephropathy. In: De Broe ME,Porter GA,Bennett WM,Verpooten GA, editors. Clinical Nephrotoxins,2nd ed. Dordrecht: Kluwer. pp 588601.
  • Dong H, Suzuki N, Torres MC, Bonala RR, Johnson F, Grollman AP, Shibutani S. 2006. Quantitative determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel electrophoresis analysis. Drug Metab Dispos 34: 11221127.
  • Grollman AP, Jelaković B. 2007. Role of environmental toxins in endemic (Balkan) nephropathy. J Am Soc Nephrol 18: 28172823.
  • Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, Suzuki N, Fernandes A, Rosenquist T, Medverec Z, Jakovina K, Brdar B, Slade N, Turesky RJ, Goodenough AK, Rieger R, Vukelić M, Jelaković B. 2007. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci USA 104: 1212912134.
  • Grollman AP, Scarborough J, Jelaković B. 2009. Aristolochic acid nephropathy: An environmental and iatrogenic disease. In: Fishbein J, editor. Advances in Molecular Toxicology 3, Amsterdam: Elsevier. pp 211222.
  • Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, Jelaković B. 2005. Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat Med J 46: 116125.
  • Hsieh SC, Lin IH, Tseng WL, Lee CH, Wang JD. 2008. Prescription profile of potentially aristolochic acid containing Chinese herbal products: An analysis of National Health Insurance data in Taiwan between 1997 and 2003. Chin Med 3: 13.
  • Hu SL, Zhang HQ, Chan K, Mei QX. 2004. Studies on the toxicity of Aristolochia manshuriensis (Guanmuton). Toxicology 198: 195201.
  • Ivić M. 1969. The problem of etiology of endemic nephropathy. Lijec Vjesn 91: 12731281.
  • Jelaković B, Karanović S, Vuković-Lela I, Miller F, Edwards KL, Nikolić J, Tomić K, Slade N, Brdar B, Turesky RJ, Stipančić Ž, Dittrich D, Grollman AP, Dickman KG. 2012. Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int 81: 559567.
  • Kensler TW, Roebuck BD, Wogan GN, Groopman JD. 2011. Aflatoxin: A 50-year odyssey of mechanistic and translational toxicology. Toxicol Sci 120( Suppl 1): S28S48.
  • Lai MN, Wang SM, Chen PC, Chen YY, Wang JD. 2010. Population-based case-control study of Chinese herbal products containing aristolochic acid and urinary tract cancer risk. J Natl Cancer Inst 102: 179186.
  • Martinčić M. 1958. Toxische einwirkungen der Aristolochia clematitis auf die Niere des Pferdes. Veterinarski Archiv 27: 5159.
  • Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelaković B, Wu L, Truong S, Fernandes A, Grollman AP. 2011. TP53 mutational signature for aristolochic acid: An environmental carcinogen. Int J Cancer 129: 15321536.
  • National Toxicology Program. 2011. Aristolochic acids. Rep Carcinog 12: 4549.
  • Nedelko T, Arlt VM, Phillips DH, Hollstein M. 2009. TP53 mutation signature supports involvement of aristolochic acid in the aetiology of endemic nephropathy-associated tumours. Int J Cancer 124: 987990.
  • Nortier JL, Martinez MC, Schmeiser HH, Arlt VM, Bieler CA, Petein M, Depierreux MF, De Pauw L, Abramowicz D, Vereerstraeten P, Vanherweghem JL. 2000. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med 342: 16861692.
  • Petronić V. 2000. Tumors of the upper urothelium and endemic nephropathy. In: Radovanović Z,Sindić M, Polenaković M, Djukanović L, Petronić V, editors. Endemic Nephropathy. Belgrade: Institue for Textbook Publishing. pp 350439.
  • Pfau W, Schmeiser HH, Wiessler M. 1990. 32P-postlabelling analysis of the DNA adducts formed by aristolochic acid I and II. Carcinogenesis 11: 16271633.
  • Rosenquist TA, Einolf HJ, Dickman KG, Wang L, Smith A, Grollman AP. 2010. Cytochrome P450 1A2 detoxicates aristolochic acid in the mouse. Drug Metab Dispos 38: 761768.
  • Schmeiser HH, Janssen JW, Lyons J, Scherf HR, Pfau W, Buchmann A, Bartram CR, Wiessler M. 1990. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 50: 54645469.
  • Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, Miller F, Grollman AP. 2010. Detoxification of aristolochic acid I by O-demethylation: Less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. Int J Cancer 127: 10211027.
  • Sidorenko VS, Yeo JE, Bonala RR, Johnson F, Schärer OD, Grollman AP. 2012. Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts. Nucleic Acids Res 40: 24942505.
  • Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, Richard C, Vandervelde D, Verbeelen D, Vanhaelen-Fastre R,Vanhaelen M. 1993. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet 341: 387391.
  • Voice TC, Long DT, Radovanovic Z, Atkins JL, McElmurry SP, Niagolova ND, Dimitrov P, Petropoulos EA, Ganev VS. 2006. Critical evaluation of environmental exposure agents suspected in the etiology of Balkan endemic nephropathy. Int J Occup Environ Health 12: 369376.
  • Yun BH, Rosenquist TA, Sidorenko V, Iden CR, Chen CH, Pu YS, Bonala R, Johnson F, Dickman KG, Grollman AP, Turesky RJ. 2012. Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem Res Toxicol 25: 11191131.
  • Zhu YP. 2002. Toxicity of the Chinese herb mu tong (Aristolochia manshuriensis). What history tells us. Adverse Drug React Toxicol Rev 21: 171177.